Literature DB >> 22021614

Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44.

Benyamin Rosental1, Michael Brusilovsky, Uzi Hadad, Dafna Oz, Michael Y Appel, Fabian Afergan, Rami Yossef, Lior Ann Rosenberg, Amir Aharoni, Adelheid Cerwenka, Kerry S Campbell, Alex Braiman, Angel Porgador.   

Abstract

NK cells play an important role in the early immune response to cancer. The NKp44 activating receptor is the only natural cytotoxicity receptor that is expressed exclusively by primate NK cells, yet its cellular ligands remain largely unknown. Proliferating cell nuclear Ag (PCNA) is overexpressed in cancer cells. In this study, we show that the NKp44 receptor recognizes PCNA. Their interaction inhibits NK cell function through NKp44/ITIM. The physical interaction of NKp44 and PCNA is enabled by recruitment of target cell PCNA to the NK immunological synapse. We demonstrate that PCNA promotes cancer survival by immune evasion through inhibition of NKp44-mediated NK cell attack.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22021614      PMCID： PMC3269963          DOI： 10.4049/jimmunol.1102267

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


  46 in total

Review 1.  Organization of DNA replication.

Authors:  Vadim O Chagin; Jeffrey H Stear; M Cristina Cardoso
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04       Impact factor: 10.005

2.  Natural killer cells: fighting viruses and much more.

Authors:  Marco Colonna; Stipan Jonjic; Carsten Watzl
Journal:  Nat Immunol       Date:  2011-02       Impact factor: 25.606

3.  Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice.

Authors:  A Cerwenka; A B Bakker; T McClanahan; J Wagner; J Wu; J H Phillips; L L Lanier
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

4.  Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus.

Authors:  Tal I Arnon; Hagit Achdout; Ofer Levi; Gal Markel; Nivin Saleh; Gil Katz; Roi Gazit; Tsufit Gonen-Gross; Jacob Hanna; Efrat Nahari; Angel Porgador; Alik Honigman; Bodo Plachter; Dror Mevorach; Dana G Wolf; Ofer Mandelboim
Journal:  Nat Immunol       Date:  2005-04-10       Impact factor: 25.606

Review 5.  Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations.

Authors:  Kerry S Campbell; Amanda K Purdy
Journal:  Immunology       Date:  2011-01-07       Impact factor: 7.397

6.  GFP-PCNA as an S-phase marker in embryos during the first and subsequent cell cycles.

Authors:  Jolanta Kisielewska; Pin Lu; Michael Whitaker
Journal:  Biol Cell       Date:  2005-03       Impact factor: 4.458

7.  Characterization of the heparin/heparan sulfate binding site of the natural cytotoxicity receptor NKp46.

Authors:  Alon Zilka; Guy Landau; Oren Hershkovitz; Noga Bloushtain; Ahuva Bar-Ilan; Fabrice Benchetrit; Eyal Fima; Toin H van Kuppevelt; John T Gallagher; Sharona Elgavish; Angel Porgador
Journal:  Biochemistry       Date:  2005-11-08       Impact factor: 3.162

8.  Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44.

Authors:  Anja Fuchs; Marina Cella; Takayuki Kondo; Marco Colonna
Journal:  Blood       Date:  2005-06-07       Impact factor: 22.113

9.  Nuclear dynamics of PCNA in DNA replication and repair.

Authors:  Jeroen Essers; Arjan F Theil; Céline Baldeyron; Wiggert A van Cappellen; Adriaan B Houtsmuller; Roland Kanaar; Wim Vermeulen
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

10.  NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis.

Authors:  M Vitale; C Bottino; S Sivori; L Sanseverino; R Castriconi; E Marcenaro; R Augugliaro; L Moretta; A Moretta
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307
View more
  96 in total

Review 1.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

2.  A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study.

Authors:  Stella M Davies; Robert Iannone; Todd A Alonzo; Yi-Cheng Wang; Robert Gerbing; Sandeep Soni; E Anders Kolb; Soheil Meshinchi; Paul J Orchard; Linda J Burns; Shalini Shenoy; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2019-12-21       Impact factor: 5.742

3.  The stalk domain and the glycosylation status of the activating natural killer cell receptor NKp30 are important for ligand binding.

Authors:  Jessica Hartmann; Thuy-Van Tran; Janina Kaudeer; Karin Oberle; Julia Herrmann; Isabell Quagliano; Tobias Abel; André Cohnen; Volker Gatterdam; Andrea Jacobs; Bernd Wollscheid; Robert Tampé; Carsten Watzl; Andreas Diefenbach; Joachim Koch
Journal:  J Biol Chem       Date:  2012-07-17       Impact factor: 5.157

Review 4.  Clinical utility of natural killer cells in cancer therapy and transplantation.

Authors:  David A Knorr; Veronika Bachanova; Michael R Verneris; Jeffrey S Miller
Journal:  Semin Immunol       Date:  2014-03-05       Impact factor: 11.130

Review 5.  NK cells after transplantation: friend or foe.

Authors:  Uzi Hadad; Olivia Martinez; Sheri M Krams
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

6.  Developmental cell death programs license cytotoxic cells to eliminate histocompatible partners.

Authors:  Daniel M Corey; Benyamin Rosental; Mark Kowarsky; Rahul Sinha; Katherine J Ishizuka; Karla J Palmeri; Stephen R Quake; Ayelet Voskoboynik; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-23       Impact factor: 11.205

7.  Central nervous system acute lymphoblastic leukemia: role of natural killer cells.

Authors:  Liron Frishman-Levy; Avishai Shemesh; Allan Bar-Sinai; Chao Ma; Zhenya Ni; Shahar Frenkel; Vera Muench; Hilke Bruckmueller; Christian Vokuhl; Klaus-Michael Debatin; Cornelia Eckert; Martin Stanulla; Martin Schrappe; Kerry S Campbell; Ron Loewenthal; Denis M Schewe; Jacob Hochman; Lueder H Meyer; Dan Kaufman; Gunnar Cario; Angel Porgador; Shai Izraeli
Journal:  Blood       Date:  2015-04-20       Impact factor: 22.113

8.  The Stalk Domain of NKp30 Contributes to Ligand Binding and Signaling of a Preassembled NKp30-CD3ζ Complex.

Authors:  Stefanie Memmer; Sandra Weil; Steffen Beyer; Tobias Zöller; Eike Peters; Jessica Hartmann; Alexander Steinle; Joachim Koch
Journal:  J Biol Chem       Date:  2016-10-17       Impact factor: 5.157

9.  Shaping of NK cell responses by the tumor microenvironment.

Authors:  Ana Stojanovic; Margareta P Correia; Adelheid Cerwenka
Journal:  Cancer Microenviron       Date:  2012-12-16

10.  Novel interaction between proliferating cell nuclear antigen and HLA I on the surface of tumor cells inhibits NK cell function through NKp44.

Authors:  Nathan C Horton; Stephen O Mathew; Porunelloor A Mathew
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.